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1. introduction 
Pyrazole and its derivatives have been widely used 
in the studies on alcohol metabolism due to their abil- 
ity to inhibit alcohol dehydrogenase. It was also 
observed that pyrazole treatment interfered with cate- 
cholamine metabolism in rat and mouse brain [ 1,2]. 
The decrease in concentration of brain noradrenaline 
(NA) was suggested to be caused by the inhibition of 
dopamine$-hydroxylase (Df3H, EC 1.14.2.1) by pyr- 
azole in vivo. This suggestion was later supported by 
the studies showing that subacute pyrazole treatment 
did, indeed, inhibit rat hypothalamic D/3H, in vivo, 
but not in vitro [3]. These results were partly con- 
firmed by a report that single doses of pyrazole 
decreased [NA] in rat brain [4]. However, chronic 
treatment with lower doses increased [NA] in rat 
brain. No change in brain DflH activity was found. 
It has been reported that 4.hydroxypyrazole (4-HP) 
is a major metabolite of pyrazole in the rat [5]. The 
effect of 4-HP on the activity of DflH was studied [6]. 
They found that D/3H activity was strongly inhibited 
by 4-HP in vitro though the inhibition was reversible 
by dialysis. 4-HP inhibited DfiH activity in plasma and 
adrenals also in vivo but DflH activity in brain remained 
unchanged. Since our preliminary studies with 4-HP 
gave quite different results in vitro we decided to study 
this subject further [7]. We present results suggesting 
that the effect of 4-HP on DPH activity is mediated 
through the inhibition of stimulatory effect of catalase 
used in the assays in vitro. 
* To whom correspondence should be addressed 
64 
2. Experimental 
D@H activity was determined by the method in [8]. 
Two different types of enzyme preparations were used 
in this study: 
(1) Bovine adrenals were homogenized in 1% Triton- 
HzO, centrifuged at 6 X lo6 X g min. D@H activ- 
ity was precipitated from the supernatant by solid 
ammonium sulphate, and the precipitate was 
dialyzed against 50 mM Tris-HCI (pH 7.4). The 
clear dialysate was fractionated in a Sephacryl 
S-200 column (equilibrated with the same buffer). 
The active fractions were concentrated on an 
Amicon ultrafiltration apparatus. This prepara- 
tion still needed extra Cu2+ in order to give maxi- 
mal activity. 
(2) Fresh bovine adrenal medullae were homogenized 
in 0.3 M sucrose and chromaffin granules were 
isolated as in [9]. Chromaffin granules were 
broken by hypotonic shock and D/3H activity was 
further purified using con A-Sepharose column 
chromatography. We thus obtained an enzyme 
preparation which was 95% pure as estimated by 
polyacrylamide gel electrophoresis. This prepara- 
tion did not need addition of any exogenous Cu2+ 
when the proper quality of catalase was used. 
3. Results and discussion 
Preliminary experiments showed that 4-HP did not 
decrease DfJH activity in vitro at 0.7 mM final cont. 
This seemed to be contradicted by the report [6] that 
DflH could be inhibited by 4-HP in vitro and that the 
Elsevier/North-Holland Biomedical Press 
Volume 120, number 1 FEBS LETTERS October 1980 
inhibition seemed to be competitive with respect to 
tyramine [6]. Catalase could be inhibited in vitro by 
4-HP, with -3 mM needed for 50% inhibition [IO]. 
We have confirmed those results and have shown that 
a 50% inhibition can be obtained at GO.1 mM depend- 
ing on the preincubation time [ 111. Based on these 
results and on the fact that catalase is an essential 
component in the assay of D/3H in vitro we have exam- 
ined the effect of concentration of 4-HP on D/3H activ- 
ity in vitro in the presence of catalase. The results are 
presented in table 1. As can be seen there is a clear 
reciprocal correlation between the [4-HP] and activ- 
ity of D/IH. However, the [catalase] used had to be 
suboptimal (20% of optimal) to demonstrate the 
inhibition. This inhibition was similar using either 
enzyme preparation. Cu’+ did not effect the inhibi- 
tion. Preincubation of enzyme with inhibitor, from 
O-60 mm, in the absence or in the presence catalase 
did not have any significant effect on the inhibition 
by 4HP. We know that preincubation of catalase with 
4-HP for 60 minutes will irreversibly inactivate cata- 
lase in the catalase assay [ 111. At the much higher 
[catalase] used in the assay of D/3H, the inactivation is 
not complete after 60 min. Only a small amount of 
catalase has to be active in order to get maximal DflH 
activity in vitro [12]. Therefore it is understandable 
that the preincubation for 60 min did not affect DPH 
inhibition by 4HP. 
This effect of catalase concentration on the DflH 
inhibition by 4HP is clearly seen in table 2. In the 
absence of catalase there was no inhibition. Instead, 
there was a small but consistent increase in D/3H activ- 
ity in the presence of 3.7 mM 4-HP. This is in agree- 
Table 1 
Effect of 4-hydroxypyrazole on the activity of dopamineQ- 
hydroxylase in vitro 
Addition of 4-HP Activity % of control 
- 5500 - 
0.74 mM 3100 51% 
1.50 mM 2250 41% 
3.70 mM 1480 26% 
Duplicate assays were done as in the text. Catalase was 
300 units/assay. The [4-HP] given in the table are the final 
concentrations in the incubation mixture. The activities are 
expressed as relative activities 
ment with the report that many nitrogen-containing 
heterocyclics stimulate D/3H [ 121. In the presence of 
catalase, especially in suboptimal concentrations, 
there is a clear inhibition of DPH activity. This inhibi- 
tion could be antagonised by increasing the concentra- 
tions of catalase. This phenomenon could be repeated 
using either enzyme preparation. An excess of catalase 
seemed to inhibit DflH activity even though it still 
protected D/3H activity against the inhibition by 4-HP. 
Based on the above results we conclude that the 
reported inhibition of D/3H by 4-HP is due to its ability 
to abolish the activation caused by catalase in the 
assay system used in vitro. It has been proposed that 
catalase in the assay in vitro stimulates D/IH in two 
different ways: (1) it destroys peroxides; and (2) it 
stabilizes the enzyme by an unknown mechanism 
(even when denatured) [ I2 ,131. Our results (not 
shown) suggest hat 4-HP inhibits D/IH activity in vitro 
mainly by competing with catalase activity. 
Table 2 
Effect of the concentration of catalase on the inhibition of dopamine-~-hydroxyl- 
ase by 4-hydroxypyrazole in vitro 
Amount of Activity % of % of control b 
catalasea control n (mean f SEM) 
Control 4-HP 
0 280 300 108 (2) 108; 112 
150 u 2610 1040 38 (6) 46.8 i 6.5 
3oou 6460 1460 22 (5) 31.2 + 4.0 
1500 u 8010 5880 67 (10) 70.0 f 3.7 
6000 U 2700 2900 107 (5) 112.0 f 4.2 
a Duplicate assays were done as in the text. The amounts of catalase are expressed 
as units/300 ~1 final vol. The activities are expressed as relative activities. 4-hy- 
droxypyrazole was 3.7 mM final cont. 
b Means and SEM are calculated from similar repeated experiments 
65 
Volume 120, number 1 FEBS LETTERS October 1980 
Hypothalamic regions are regions of high-perme- 
ability in the brain [ 141. Therefore we can not exclude 
the possibility that the effects of pyrazole on brain 
biogenic amine levels and DPH activity in hypothala- 
mus are due to the formation of 4HP. 4-HP could 
locally inactivate catalase and thus locally increased 
levels of peroxides could be a cause for inactivation 
of DpH. However, we have found that other pyrazole 
derivatives which are incapable of being metabolised 
to 4-HP possess imilar brain noradrenaline lowering 
effects as pyrazole thus suggesting another mecha- 
nism [2]. 
The assay of D/3H is full of pitfalls, as documented 
in [ 151. Therefore one has to be very careful in inter- 
preting sometimes conflicting results. 
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